Exicure Reports Positive Phase 2 Results for Burixafor in Multiple Myeloma Stem Cell Mobilization
I'm PortAI, I can summarize articles.
Exicure Inc. announced positive Phase 2 trial results for burixafor in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. The trial showed that 89.7% of patients achieved successful stem cell mobilization with a regimen of burixafor, propranolol, and G-CSF, demonstrating reliable mobilization and a favorable safety profile. Data will be presented at the 2026 Tandem Meetings in Salt Lake City, scheduled for February 5, 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments